SPL
$307MCF+
Starpharma
Biotech · Drug delivery
DEP dendrimer drug delivery platform, DEP cabazitaxel in Phase 2 for solid tumours
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$18.3M
Dec 2025 4C
Runway
CF+Cash Flow Positive
Based on Dec 2025 4C
Market Cap
$307M
Burn Rate
—
Dec 2025 4C
Shares Outstanding
421M
Pipeline Assets
2
Latest Insight(1)
20 Apr 2026clinical_milestoneFDA confirms path to DEP HER2 first-in-human study
FDA confirmed alignment on the clinical development strategy and design of the first-in-human phase 1 study for DEP® HER2, a HER2-targeting dendrimer conjugate with lutetium-177 payload. The study is on track to begin in H2 2026 in Europe with up to 15 patients.
DEP® HER2·locally advanced or metastatic HER2-overexpressing gastric/gastro-oesophageal junction cancers and other HER2 expressing advanced cancers·positive
3M Price
SPL.ASX$0.730+111.6% 3M
Low $0.340High $0.730
Pipeline Assets (2)
DEP cabazitaxelSolid tumours
Phase 2DEP irinotecanSolid tumours
Phase 2Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
DEP cabazitaxel
Solid tumours
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Transactions
1 transactionLast 90dNet Sell
Buys0
Sells1+1 vs prior
Sell Value$673k
$672,6932026-02-16
51d before · Results posted — Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)
Substantial Holders (5%+ threshold)
6 noticesCEASEDUBS Group AG and its related bodies corporate
CEASEDUBS Group AG and its related bodies corporate
INITIALUBS Group AG and its related bodies corporate
6.49%2026-03-03
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-03-27 · 4-day lag
Short position
0.09%
arrow_drop_down0.00% over 30 reports
Shares short
0.4M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
Competitive Landscape
1000 competitor trialsPhase 2+ · Non-ASX
Solid Tumours1000 active trials
275 Ph2725 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
1 paper
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Catalysts (12)· 1 upcoming · 11 past
DEP cabazitaxel Phase 2 update
UpcomingExpectedremoveMed30 Sept 2026
expand_more11 past catalysts
Confirmedarrow_upwardHigh8 Apr 2026
Results available at https://clinicaltrials.gov/study/NCT01201057
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
1/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Hit 1 of 1 guided dates· rolling 2yr(limited sample)· of 12 tracked
Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.
Completed catalysts
✓DEP® HER2 (DEP® HER2 first-in-human phase 1 study) — FDA confirms path to DEP HER2 first-in-human study— FDA confirmed alignment on the clinical development strategy and design of the first-in-human phase 1 study for DEP® HER2, a HER2-targeting dendrimer conjugate with lutetium-177 payload. The study is on track to begin in H2 2026 in Europe with up to 15 patients.
On time
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
★ RESULTS
Announcements(8)
science
clinical_milestonePSauto_awesome
FDA confirms path to DEP HER2 first-in-human study20 Apr 2026
expand_more176KB